Guardant Health, INC Form 4 insider transactions

Guardant Health Director Manuel Hidalgo Medina reported the vesting and conversion of 232 restricted stock units into common stock.

Guardant Health Director Tariq Musa reported the vesting of 250 restricted stock units into common stock, increasing his direct ownership.

Guardant Health Director Manuel Hidalgo Medina exercised stock options and subsequently sold 1,500 shares of common stock on November 7, 2025.

Guardant Health's Chief Legal Officer, John G. Saia, reported a planned future sale of 8,996 shares of common stock at $96.25 per share under a Rule 10b5-1 plan.

Guardant Health Director Steve Krognes converted 154 Restricted Stock Units into common stock on October 31, 2025, as part of a pre-scheduled vesting.

Guardant Health Director Roberto Mignone acquired 3,167 shares of common stock through the vesting of restricted stock units.

Guardant Health Director Manuel Hidalgo Medina acquired 232 shares of common stock through the vesting of Restricted Stock Units on October 17, 2025.

Guardant Health Director Tariq Musa sold 116 shares of common stock for $66.95 per share on October 17, 2025, under a pre-arranged Rule 10b5-1 plan.

Guardant Health Director Myrtle S. Potter sold 26 shares of common stock for $66.95 per share under a pre-arranged Rule 10b5-1 plan.

Guardant Health Director Musa Tariq acquired 250 shares of common stock through the vesting of restricted stock units.

Myrtle S. Potter, a Director at Guardant Health, Inc., reported the vesting of 69 shares of common stock.

Guardant Health's Chief Legal Officer, John G. Saia, increased his direct beneficial ownership of common stock to 52,168 shares following the vesting of restricted stock units and subsequent tax-related sales.

Guardant Health's Chief People Officer, Terilyn J. Monroe, reported the vesting of restricted stock units and subsequent tax-related share withholding.

Guardant Health's Chief Information Officer, Kumud Kalia, reported the vesting of restricted stock units and the sale of shares to cover tax obligations.

Guardant Health's Chief Commercial Officer, Chris Freeman, reported routine acquisitions of common stock through restricted stock unit vesting and subsequent tax-related dispositions.

Guardant Health's Chief Medical Officer, Craig Eagle, reported the vesting of restricted stock units and a corresponding disposition of shares for tax obligations.

Guardant Health's Chief Technology Officer, Darya Chudova, reported the vesting of restricted stock units and subsequent share disposition for tax obligations on October 1, 2025.

Guardant Health's CFO, Michael Brian Bell, increased his direct beneficial ownership of common stock through RSU vestings and a tax-related disposition.

Guardant Health Co-CEO AmirAli Talasaz reported the vesting of restricted stock units and subsequent tax-related share dispositions.

Guardant Health Director Steve Krognes converted 154 restricted stock units into common stock on September 30, 2025, increasing his direct common stock holdings.

Guardant Health Co-CEO Helmy Eltoukhy reported recent acquisitions of common stock through RSU vesting and subsequent tax-related dispositions.

Guardant Health Director Alex M. Azar II was granted stock options and restricted stock units totaling 17,136 shares, vesting over four years.

Guardant Health Director Manuel Hidalgo Medina acquired 232 shares of common stock through the vesting of restricted stock units.

Guardant Health Director Tariq Musa reported the acquisition of common stock through RSU vesting and a subsequent sale of a portion of his holdings.

Guardant Health Director Myrtle S. Potter reported the vesting of 68 restricted stock units and the subsequent sale of 26 common shares under a Rule 10b5-1 plan.

Guardant Health's Chief Legal Officer, John G. Saia, vested 1,019 restricted stock units and sold 535 shares to cover tax obligations.

Guardant Health's Chief Information Officer, Kumud Kalia, reported the vesting of restricted stock units and subsequent share transactions, including tax-related dispositions.

Guardant Health's Chief Commercial Officer, Chris Freeman, reported the vesting of restricted stock units and subsequent tax-related share disposition.

Guardant Health's Chief Medical Officer, Craig Eagle, reported the vesting of restricted stock units and subsequent tax-related share disposition.

Guardant Health CFO Michael Brian Bell reported the vesting of restricted stock units, leading to an increase in common stock holdings and a sale of shares for tax obligations.